Skip to main content

Table 1 Baseline characteristics of the patients

From: Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial

Characteristics

Colchicine (n = 120)

Placebo (n = 129)

P value

Age, year (mean ± SD)

56.9 ± 7.56

56.89 ± 7.45

0.993

Male sex, no. (%)

86 (71.7)

87 (67.4)

0.939

Hypertension, no. (%)

52 (43.3)

59 (45.7)

0.703

Diabetes, no. (%)

27 (22.5)

32 (24.8)

0.669

Current smoking or opium use, no. (%)

52 (43.3)

49 (38.0)

0.39

Hyperlipidemia, no. (%)

37 (30.8)

36 (27.9)

0.78

History of myocardial infarction, no (%)

10 (8.3)

12 (9.3)

0.788

History of PCI, no. (%)

16 (13.3)

20 (15.5)

0.627

History of CABG, no. (%)

4 (3.3)

3 (2.3)

0.714

History of heart failure, no. (%)

4 (3.3)

5 (3.9)

0.819

History of TIA or CVA, no. (%)

5 (4.2)

4 (3.1)

0.653

Admission diagnosis

   

 STEMI

64 (53.3)

64 (50.4)

0.557

 NSTEMI + UA

56 (46.7)

65 (49.6)

0.642

 UA

41 (34.2)

45 (34.8)

0.905

 NSTEMI

15 (12.5)

20 (14.8)

0.496

 Number of patients underwent PCI

104

111

0.887

PCI to culprit vessel

   

 LAD

54

62

0.628

 LCX (OM)

20

23

0.808

 RCA

23

21

0.551

 Ramus

2

2

0.942

 PDA

5

3

0.41

  1. PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; TIA, transients ischemic attack; CVA, cerebrovascular accident; STEMI, ST segment elevation myocardial infarction; NSTEMI, non-ST segment elevation acute coronary syndrome; UA, unstable angina; LAD, left anterior descending; LCx, left circumflex; OM, obtuse marginal; RCA, right coronary artery; PDA, posterior descending artery